Redirecting to https://northeast.newschannelnebraska.com/story/52907044/avenzo-therapeutics-announces-first-patient-dosed-in-phase-12-clinical-study-of-avzo-1418-a-potential-best-in-class-egfrher3-bispecific-antibody-drug